Verve Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	9.51	8.27	6.57
Other Revenue	-	-	0
Revenue	9.51	8.27	6.57
Revenue Growth (YoY)	15.05%	25.82%	-
Cost of Revenue	8.91	7.12	5.55
Gross Profit	0.6	1.15	1.02
Selling, General & Admin	2.5	2.28	1.87
Other Operating Expenses	0.12	-0	-0.01
Operating Expenses	3.11	2.79	2.27
Operating Income	-2.51	-1.64	-1.26
Interest Expense	-0.4	-0.4	-0.23
Interest & Investment Income	0	0	0
Earnings From Equity Investments	0.04	0.04	-
Currency Exchange Gain (Loss)	-0	-0.02	-0
Other Non Operating Income (Expenses)	-0	-0.1	-0.01
EBT Excluding Unusual Items	-2.87	-2.11	-1.49
Gain (Loss) on Sale of Assets	-0.02	-0.02	0.04
Asset Writedown	-0.34	-0.16	-0.15
Other Unusual Items	0.15	-1.28	-0.02
Pretax Income	-3.07	-3.57	-1.62
Income Tax Expense	-0.16	-0.14	-0.13
Net Income	-2.92	-3.43	-1.49
Net Income to Common	-2.92	-3.43	-1.49
Shares Outstanding (Basic)	3	3	-
Shares Outstanding (Diluted)	3	3	-
Shares Change (YoY)	2.11%	-	-
EPS (Basic)	-0.85	-1.02	-
EPS (Diluted)	-0.85	-1.02	-
Free Cash Flow	-	-3.09	-
Free Cash Flow Per Share	-	-0.92	-
Gross Margin	6.32%	13.88%	15.48%
Operating Margin	-26.38%	-19.80%	-19.11%
Profit Margin	-30.68%	-41.52%	-22.64%
Free Cash Flow Margin	-	-37.42%	-
EBITDA	-1.94	-1.07	-0.84
EBITDA Margin	-20.42%	-12.95%	-12.86%
D&A For EBITDA	0.57	0.57	0.41
EBIT	-2.51	-1.64	-1.26
EBIT Margin	-26.38%	-19.80%	-19.11%
Revenue as Reported	9.57	8.48	6.79

Source: S&P Global Market Intelligence. Standard template. Financial Sources.